Biogen reports two-year Phase II data for diranersen in Alzheimer’s
The trial evaluated diranersen in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer's.
The trial evaluated diranersen in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer's.